The 67th American Society of Hematology (ASH) Annual Meeting showcased groundbreaking advancements in multiple myeloma treatment, including innovative CAR T-cell therapies, bispecific antibodies, and novel approaches like in vivo gene delivery and dual-targeting therapies. Highlights included promising results from studies on ciltacabtagene autoleucel, teclistamab-daratumumab combinations, and emerging therapies such as linvoseltamab and cevostamab for post-CAR T-cell consolidation. These treatments demonstrated deep responses, improved progression-free survival (PFS) and overall survival (OS), and manageable safety profiles. With a focus on reducing toxicities, enhancing accessibility, and addressing high-risk and relapsed/refractory cases, these advancements are paving the way for more effective and personalized myeloma care.
